drugset / Trial / NCT02564575
Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of the HPIV3-EbovZ GP Ebola vaccine candidate in healthy adults.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HPIV3-EbovZ GP | Vaccine | 1e+06 unknown | Intranasal |
| Subject | HPIV3-EbovZ GP | Vaccine | 1e+07 unknown | Intranasal |